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bjectives The aim of this study was to compare outcomes among unselected patients undergoing
ercutaneous coronary intervention (PCI) with either sirolimus-eluting (SES) or paclitaxel-eluting
tents (PES).
ackground Although the beneﬁts of both SES and PES are well-established, studies comparing
hese stents directly have yielded conﬂicting results.
ethods We used data from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events)
egistry to compare in-hospital and 1-year outcomes among unselected patients undergoing non-
mergent PCI with either SES or PES implantation.
esults Between July 2004 and June 2006, 6,035 patients underwent PCI with either SES
n  3,443) or PES (n  2,592) at 47 U.S. centers. Baseline clinical and angiographic characteristics
ere generally similar for the 2 stent types. At 1-year, there were no differences in the primary end
oint of cardiac death or myocardial infarction (MI) between the SES and PES groups (9.1% vs.
0.0%, p  0.11) or in any individual end points including cardiac death, nonfatal MI, or stent
hrombosis. In unadjusted analyses, target lesion revascularization (TLR) was slightly more common
ith SES than with PES (4.4% vs. 3.3%, p  0.048), but this difference was no longer apparent after
djusting for baseline characteristics as well as site-related factors (adjusted hazard ratio: 1.09, 95%
onﬁdence interval: 0.78 to 1.50).
onclusions Among unselected patients undergoing PCI, adjusted rates of both ischemic complica-
ions as well as clinically important restenosis were similar for SES and PES. The unexpected ﬁnding
hat TLR was inﬂuenced by site characteristics suggests that the correlation between TLR and angio-
raphic restenosis might be weaker than previously described and warrants further study. (J Am
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768y reducing neointimal hyperplasia after vascular injury,
rug-eluting (coronary) stents (DES) decrease late luminal
oss and angiographic restenosis, as compared with bare-
etal stents (BMS) (1,2). The first 2 DES approved for
linical use, a polymer-encapsulated stent releasing siroli-
us (SES) (Cypher, Cordis, Johnson & Johnson, Miami,
lorida) and a polymer-based, paclitaxel-eluting stent
PES) (Taxus, Boston Scientific, Natick, Massachusetts)
ave been shown to reduce the rates of angiographic and
linical restenosis in several randomized trials (1,2).
See page 776
Although the therapeutic benefits of SES and PES over
MS are well-established, there might be differences between
he 2 devices. Randomized clinical trials comparing SES with
ES directly have demonstrated divergent results. In some
studies, the 2 stents were found to
be comparable in terms of clinical
outcomes (3,4), whereas others
have demonstrated superior out-
comes with SES—especially in
terms of repeat revascularization
(5,6).
Although randomized clinical
trials remain the “gold standard”
for therapeutic comparisons and
are the most reliable means to
eliminate confounding, random-
ized trials are not without limi-
tations. Compared with regis-
tries, the patient population
enrolled in randomized trials is
often smaller, limiting statistical
power to resolve small but po-
tentially important differences—
articularly for rare outcomes. In addition, most clinical
rials restrict enrollment to selected patients, thus limiting the
eneralizability of their findings. Finally, randomized trials
particularly those conducted for regulatory purposes) often
ncorporate routine angiographic follow-up, which can in-
uence the rates of subsequent clinical end points via the
oculostenotic reflex” (7–9). Although certain of these
imitations might be overcome by observational study de-
igns (in particular, issues related to sample size and
eneralizability), in many cases observational studies lack
ufficient clinical or angiographic detail to perform adequate
tents and Ischemic Events) and its analysis was provided by grants from Millennium
harmaceuticals and Schering Plough Incorporated. In the past 5 years, Dr. Cohen has
eceived grant support from Cordis and Boston Scientific. Dr. Kleiman has received
esearch support from Cordis, Eli Lilly, Medtronic, Sanofi Aventis, and The Medicines
bbreviations
nd Acronyms
CS  acute coronary
yndrome
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
M  diabetes mellitus
R  hazard ratio
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularizationompany; honoraria for speaking engagements from Sanofi Aventis, Cordis, Medtronic,
M
aisk-adjustment—particularly when the data are collected
ainly for administrative purposes.
The EVENT (Evaluation of Drug Eluting Stents and
schemic Events) registry is a multicenter, observational study
f unselected patients undergoing percutaneous coronary in-
ervention (PCI) with planned implantation of Food and Drug
dministration–approved intracoronary stents (10). The
VENT registry collects detailed data regarding sociodemo-
raphic, clinical, angiographic, and procedural factors, and all
atients undergo clinical follow-up at 6 and 12 months. By
esign, the EVENT registry includes a broad geographic
epresentation of hospitals and practice settings (public/private,
cademic, and so forth) and therefore provides a cross-sectional
snapshot” of the practice of PCI in the U.S. In this study, we
sed data from the EVENT registry to assess contemporary
.S. practice with regard to stent selection and to compare the
-year outcomes of patients after nonemergent PCI with either
ES or SES implantation in a large, unselected patient
opulation.
ethods
atient population. The design of the EVENT registry has
een described elsewhere (10,11). Briefly, the registry is de-
igned to include consecutive, unselected patients undergoing
onemergent PCI at multiple centers within the U.S. Enroll-
ent has been performed in 4 discrete intervals (“waves”) of
pproximately 2,500 patients each in order to assess changes in
ontemporary interventional practice over time. The current
nalysis includes patients enrolled in the first 3 waves of the
egistry, which occurred between July 2004 and June 2006.
Data concerning patient characteristics, clinical presenta-
ion, and treatment were collected prospectively at each study
ite with standardized case report forms and submitted to the
ata coordinating center. Patients were contacted by study
ersonnel at 6 and 12 months after the index PCI to assess the
ccurrence of pre-specified clinical end points including death,
yocardial infarction (MI), repeat revascularization, and stent
hrombosis. When events were suspected, the local study
oordinator attempted to obtain supporting medical records to
ocument the event. For the present analysis we included all
atients who underwent PCI for reasons other than acute
T-segment elevation MI and received at least 1 commercially
vailable DES (SES or PES). Patients in whom both types of
ES were deployed were excluded from the analysis, whereas
atients in whom both DES and BMS were used were
nalyzed according to DES type. The study protocol was
pproved by ethical review committees at all participating
nd the Medicines Company; and has served as a consultant to Boston Scientific and
edtronic. Dr. Mauri has served as consultant to Cordis and Medtronic.anuscript received February 9, 2009; revised manuscript received May 15, 2009,
ccepted May 29, 2009.
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769nstitutions, and all patients provided written informed
onsent.
eﬁnitions, adjudication of events, and study outcomes.
he primary end point was the composite of cardiac death
r MI at 1 year. To ensure uniform ascertainment of
schemic events, the study protocol specified that total
reatine kinase and creatine kinase-myocardial band (CK-
B) would be collected at baseline and a minimum of 8 and
6 h after the procedure until a peak was observed. The
nzymatic criterion for MI was elevation of CK-MB 3
he local upper limit of normal; if the baseline CK-MB
alue was elevated, the peak value was required to be at least
 the baseline level as well (10). Secondary end points
ncluded the individual components of the primary end
oint; target lesion revascularization (TLR); and stent
hrombosis (definite or probable according to the Academic
esearch Consortium classification) (12) at 1-year and
ardiac death or MI during the index hospital stay. Target
esion revascularization was site-reported and was defined as
ny revascularization procedure performed because of a
tenosis within the original stented lesion or within 5 mm of
he stent margins (1).
tatistical methods. Normally distributed continuous vari-
bles are presented as mean  SD and were compared by
tudent t test. Non-normally distributed continuous variables
re presented as median values and interquartile ranges and
ere compared by the Mann-Whitney test. Discrete variables
ere compared by the chi-square test or Fisher’s exact test
hen appropriate. Estimated 12-month rates of the primary
nd secondary end points were determined with the Kaplan-
eier method and compared with the log-rank statistic.
To adjust for differences between the stent groups, we
sed multiple logistic regression for the analysis of in-
ospital outcomes and Cox proportional hazards regression
odels for the 12-month end points. Adjustment for
otential covariates was performed in a sequential manner.
irst, each comparison was adjusted for baseline clinical and
emographic characteristics: age, sex, diabetes, history of
ypass surgery, ejection fraction (divided into 4 groups:
25%, 25% to 35%, 36% to 50%,50%), weight, estimated
lomerular filtration rate (based on the Cockroft-Gault
ormula) (13), and acute coronary syndrome as the indica-
ion for PCI. Next, we added adjustments for angiographic
actors: number of diseased vessels, number of lesions,
ngiographic thrombus, treatment of a bifurcation lesion,
reatment of a left anterior descending artery lesion, treat-
ent of a totally occluded lesion, and vessel diameter
assessed by maximal balloon diameter). Finally, procedural
haracteristics were introduced: planned use of a glyco-
rotein IIb/IIIa inhibitor or bivalirudin, total stent length,
se of overlapping stents, and pre-procedural clopidogrel
oading. To avoid model overfitting, at each step of our
equential analysis, we used forward stepwise regression to
dentify potential significant predictors (p  0.10) foretention in the model; and DES type (SES vs. PES) was
orced into the resulting model. Proportionality of the
azard associated with type of DES was verified by assessing
he interaction term between the time-log and the stent type.
Finally, because stent selection might be associated with
ertain practice characteristics, we investigated the impact of
tent preference at the site level on clinical outcomes. This
as done by dividing the sites into approximately equal-
ized groups on the basis of the proportion of DES
mplanted during the study period that were SES (50%,
0% to 80%, 80%). This 3-level categorical variable and
ts interaction with treatment group were included as
otential covariates in the final stage of our analysis (14).
esults
etween July 2004 and June 2006, 7,593 patients were
nrolled in Waves 1, 2, and 3 of the EVENT registry. We
xcluded 584 patients who were undergoing primary PCI
or ST-segment elevation MI, 824 patients with no DES
eployed, and 150 patients who received both SES and
ES. Of the 6,035 patients eligible for inclusion in the
urrent analysis, SES were deployed in 3,443 (57.1%) and
ES were deployed in 2,592 (42.9%). Hospital discharge
ata were available for all patients, and 1-year follow-up was
btained in 5,890 (97.6%). The proportion of SES im-
lanted ranged from 0% to 93% over the 47 sites (Fig. 1).
verall, the proportion of SES use was 51.9% in Wave 1,
0.8% in Wave 2, and 58.4% in Wave 3.
aseline characteristics. Baseline clinical characteristics
ere generally similar between the 2 stent groups (Table 1).
atients in the PES group were more likely to have
ndergone PCI in the setting of an acute coronary syn-
rome and less likely to have chronic stable angina or a
ositive stress test as indications for revascularization.
Figure 1. Proportion of SES Use (Among All Drug-Eluting Stent Proce-
dures) in the 47 EVENT Registry HospitalsSES  sirolimus-eluting stent.
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770Angiographic characteristics including the number of lesions
reated as well as high-risk lesion characteristics also tended to
e similar between the 2 groups (Table 2). Intervention in left
nterior descending artery lesions and totally occluded lesions
ere more common in the SES group; in contrast, lesions in
Table 1. Baseline Demographic and Clinical Characte
Demographic
Age, yrs, mean  SD
Male
Medical history
Diabetes
Hypertension
Hyperlipidemia
Current smoking
Renal dialysis
Stroke
Congestive heart failure
Peripheral arterial disease
Previous MI
MI within 7 days of PCI
Previous PCI
Previous CABG
Indication for PCI
Acute coronary syndrome
Chronic stable angina or positive stress test
Other
Off-label indication for the PCI*
Ejection fraction
25%
25%–35%
36%–50%
50%
Unknown
Baseline laboratory data
Creatinine 2.0 mg/dl
Estimated creatinine clearance, ml/min†
Medications before PCI
Statin
Beta blocker
ACE inhibitor
Angiotensin receptor blocker
Number of diseased vessels
1
2
3
Lesions/patient, mean  SD
*Criteria for off-label use (at least 1 of the following, calculated only for
bifurcation lesion, lesion in bypass graft, baseline creatine kinase my
maximum balloon diameter4 mm, left ventricular ejection fraction
was estimated by Cockcroft and Gault equation.
ACE  angiotensin-converting enzyme; CABG  coronary artery
intervention; PES paclitaxel-eluting stent; SES sirolimus-eluting sthe PES group were more likely to have reduced flow (Throm- Iolysis In Myocardial Infarction flow grade 0 to 2) and more
ikely to have angiographic thrombus.
rocedural characteristics. Procedural factors including an-
ithrombotic therapies are summarized in Table 3. Patients
n the PES group were more likely to receive a glycoprotein
s
Group
3,443)
PES Group
(n  2,592) p Value
 11.7 64.7  11.0 0.09
.7% 68.8% 0.40
.7% 35.2% 0.69
.0% 79.3% 0.79
.6% 73.2% 0.002
.4% 23.3% 0.44
.5% 1.8% 0.32
.0% 8.8% 0.78
.8% 10.1% 0.65
.7% 11.1% 0.07
.8% 34.2% 0.78
.7% 8.9% 0.71
.0% 38.1% 0.47
.8% 22.4% 0.12
0.001
.4% 39.3%
.7% 53.7%
.9% 6.9%
.9% 49.2% 0.002
0.24
.4% 2.4%
.6% 5.5%
.1% 18.7%
.0% 55.8%
.0% 17.7%
.6% 3.1% 0.25
 43.6 88.7  43.8 0.35
.2% 64.3% 0.002
.6% 69.0% 0.64
.3% 39.2% 0.92
.0% 13.4% 0.13
.3% 51.6% 0.18
.3% 27.9%
.5% 20.5%
 0.61 1.34  0.61 0.14
with all data available):1 lesion treated, total stent length36mm,
l band 3 upper limit of normal, stenosis pre-procedure  100%,
and unprotected left main artery intervention. †Creatinine clearance
grafting; MI  myocardial infarction; PCI  percutaneous coronaryristic
SES
(n 
64.2
67
34
79
76
22
1
9
9
9
33
8
39
20
32
59
7
53
2
6
20
54
17
3
87.6
68
69
39
12
49
30
20
1.36
subjects
ocardia
25%,
bypassIb/IIIa inhibitor as part of their antithrombotic regimen
b
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771ut less likely to have received clopidogrel loading before
CI, consistent with the higher incidence of acute coronary
yndromes. Maximum balloon diameter and total stent
ength were slightly greater for the SES group.
Table 2. Angiographic Characteristics
Per Lesion
SES Gro
(n  4,683 L
Lesion location
LAD 37.6%
Circumﬂex 22.3%
RCA 31.5%
LMCA 1.6%
SVG 7.0%
ACC/AHA lesion classiﬁcation
A 11.3%
B1 32.5%
B2 37.2%
C 19.1%
Lesion characteristics
% stenosis, mean  SD 83.5  11
Total occlusion 5.4%
Bifurcation 11.3%
Angiographic thrombus 6.2%
TIMI ﬂow grade
0 5.4%
1 2.8%
2 6.9%
3 84.9%
Vessel diameter (mm)* 3.15  0.
Lesion length† 22.99  12
Per lesion analysis. *Estimated on the basis of maximum balloon diam
ACC/AHAAmericanCollegeofCardiology/AmericanHeartAssocia
RCA right circumflex artery; SVG saphenous vein graft; TIMI Th
Table 3. Procedural Characteristics
SES
Medications during the procedure
Heparin 5
Glycoprotein IIb/IIIa inhibitor 4
Direct thrombin inhibitor 4
Other
Clopidogrel loading* 3
Stents implanted
Mean  SD 1.60
Median (interquartile range) 1.00 (1
More than 1 stent in at least 1 lesion 2
Total stent length, mean  SD 30.7
Statins at discharge 8
Clopidogrel at discharge† 9
Per patient analysis. *Clopidogrel loading defined as chronic therapy (
loading dose (600 mg) at least 2 h before PCI. †Captured in waves 2Abbreviations as in Table 1.rocedural and in-hospital outcomes. The DES deployment
as unsuccessful in 0.7% of the lesions attempted with SES
nd 1.4% with PES (p  0.001), whereas side branch
cclusion was somewhat more frequent with SES vs. PES
)
PES Group
(n  3,465 Lesions) p Value
0.018
34.7%
24.6%
32.7%
1.2%
6.8%
0.36
11.9%
34.1%
33.5%
20.4%
84.2  11.2 0.006
3.8% 0.001
10.9% 0.654
9.4% 0.001
0.001
5.2%
5.2%
10.5%
79.1%
3.08  0.49 0.001
21.39  11.81 0.001
stimated on the basis of total stent length.
D left anterior descendingartery; LMCA leftmain coronary artery;
sis In Myocardial Infarction; other abbreviations as in Table 1.
PES Group p Value
58.9% 0.64
40.0% 0.62
42.6% 0.72
4.3% 0.99
41.8% 0.003
1.55  0.86 0.043
00) 1.00 (1.00–2.00)
18.5% 0.008
28.2  18.8 0.001
76.6% 0.001
96.8% 0.07
before treatment); loading dose (300mg) at least 6 h before PCI; or
3,994 subjects).up
esions
.3
56
.97
eter. †E
tion; LAGroup
9.5%
0.6%
2.1%
4.3%
8.0%
 0.85
.00–2.
1.3%
 19.7
3.9%
5.7%
1week
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7721.6% vs. 1.0%, p  0.02). Overall, there was no significant
ifference in the incidence of angiographic success; the
roportion of lesions with a final diameter stenosis 30%
fter stent implantation was 0.8% for SES and 1.1% for
ES stented lesions (p  0.30). There were no significant
ifferences in in-hospital clinical outcomes between the
tent groups, although there was a trend toward slightly
ore frequent periprocedural MI in the PES group (7.1%
s. 6.0%, p  0.07).
ne-year clinical outcomes. At 1 year after the index pro-
edure, there were no differences in the incidence of cardiac
eath, nonfatal MI, or their composite between the SES
nd PES groups (Table 4, Fig. 2A). The incidence of
cademic Research Consortium definite or probable stent
hrombosis was similar between the 2 stent groups as well
0.9% vs. 1.2%, p  0.27). However, the incidence of TLR
t 1 year was slightly higher among the SES group com-
ared with PES group (4.4% vs. 3.3%, p  0.02).
In risk-adjusted analyses, there were no significant dif-
erences in the composite outcome of cardiac death or MI or
n-stent thrombosis at 1 year, and the adjusted hazard ratios
HRs) remained virtually unchanged from the univariate
esults (Figs. 3A and 3B). The adjusted HR for TLR
emained higher with SES after adjustment for clinical,
ngiographic, and procedural characteristics. After adjusting
or site-level stent selection (i.e., high/intermediate/low
ES use), however, this difference was markedly attenuated
nd no longer statistically significant (fully adjusted HR:
Table 4. Clinical Outcomes During the Index Hospital Stay and at 1 Year
SES
Group
PES
Group
p
Value
Procedural outcomes
Unsuccessful DES deployment 0.9% 1.8% 0.001
Side branch occlusion 2.1% 1.3% 0.02
No reﬂow 0.8% 0.4% 0.08
Angiographic success* 99.2% 98.9% 0.30
In hospital
Death 0.1% 0.1% 1.00
MI 6.0% 7.1% 0.07
Death or MI 6.1% 7.2% 0.09
At 1 yr†
Cardiac death 1.6% 1.7% 0.64
MI 7.9% 8.8% 0.18
Cardiac death or MI 9.1% 10.0% 0.11
Any death 2.8% 2.9% 0.84
TLR 4.4% 3.3% 0.02
Cardiac death, MI, or TLR 12.3% 12.4% 0.78
Stent thrombosis 0.9% 1.2% 0.27
*Angiographic success defined as a final diameter stenosis30%after stent implantation.†One-
year rates are based on Kaplan-Meier estimates.
DES  drug-eluting stent(s); TLR  target lesion revascularization, other abbreviations as in
Table 1..09, 95% confidence interval: 0.79 to 1.51). There were mlso no significant differences in risk-adjusted ischemic
cardiac death or MI) or restenosis-related (TLR) outcomes
y stent type over a broad range of subgroups, including
atients with or without diabetes, acute coronary syndrome,
Figure 2. Kaplan-Meier Survival Curves
Kaplan-Meier survival curves for time to cardiac death or myocardial infarc-
tion (MI) (A), time to deﬁnite or probable stent thrombosis (B), and time to
target lesion revascularization (C). PES  paclitaxel-eluting stent(s); SES 
sirolimus-eluting stent(s).ultivessel disease, or off-label DES use (Figs. 4A and 4B).
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773Rates of clopidogrel use were similar among SES and
ES recipients at 6 months (88.1% vs. 89.1%, p 0.21) but
Figure 3. Cox Proportional Hazard Regression Derived Hazard Ratios
Cox proportional hazard regression derived hazard ratios comparing SES
versus PES for the end points of cardiac death or MI (A), target lesion
revascularization (B), and stent thrombosis (C) at 12 months (with 95%
conﬁdence interval). Hazard ratios are derived from risk-adjustment models
with sequential inclusion of baseline clinical characteristics, lesion charac-
teristics, procedural characteristics, and site characteristics as described in
the Methods section. Abbreviations as in Figure 2.lightly higher among SES recipients at 12 months (83.1%s. 80.3%, p 0.01). Rates of statin use were slightly higher
mong SES versus PES recipients at both 6 and 12 months
95.5% vs. 94.2% and 96.1% vs. 94.3%, respectively; p 
.05 for both comparisons). Inclusion of 6-month clopi-
ogrel and statin use as additional covariates in our multi-
ariable analysis had no major impact on the adjusted HRs
or the 1-year outcome comparisons.
The incidence of each clinical outcome at 1 year, stratified
y both DES type and site-level stent preference (by tertile)
s displayed in Table 5. For the end points of cardiac
eath/MI and stent thrombosis, there was no evidence of a
ite level effect on clinical outcomes. For TLR, however,
ites that used 80% SES had significantly higher rates
han those sites with either 50% to 80% or 50% SES use
5.3% vs. 3.2% vs. 3.5%, respectively; p  0.001). None-
heless, there was no evidence of a significant interaction
etween site-level stent use and the impact of DES type on
ny of the clinical outcomes.
Figure 4. Adjusted Hazard Ratios (SES vs. PES) for Cardiac Death
or MI and TLR
Adjusted hazard ratios (SES vs. PES) for cardiac death or MI (A) and TLR (B)
among pre-speciﬁed subgroups. ACS  acute coronary syndrome; DM 
diabetes mellitus; TLR  target lesion revascularization; other abbreviations
as in Figure 2.
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774iscussion
lthough both SES and PES have been available for more
han 5 years, there is still controversy as to the relative
linical utility of these 2 devices. Given the large volume of
CI procedures performed annually (nearly 1 million in the
.S. alone), most of which involve placement of DES, the
ssue of stent selection continues to have important public
ealth implications. In this study, we used data from a large,
rospective multicenter registry conducted at 47 diverse
.S. centers to examine this issue.
The main result of our study was that, among unselected
atients undergoing PCI between 2004 and 2006 (the
eriod of maximum DES penetration in U.S. practice), SES
nd PES were quite similar in terms of both ischemic
omplications (cardiac death, MI, stent thrombosis) as well
s clinical restenosis (TLR) at 1 year after nonemergent
evascularization. Moreover, we found no important differ-
nces in clinical outcomes across a broad range of patient
ubgroups.
omparison with previous studies. Most early clinical trials
including those that incorporated routine angiographic
ollow-up) have tended to favor the SES in terms of both
LR and stent thrombosis (3,6,15–17). More recently,
linical trials without angiographic follow-up (4) as well as
egistry studies (18,19) have found few, if any, differences in
linical outcomes between the 2 types of DES. The most
ikely explanation for the difference in stent performance
etween the randomized trials and the registry-based studies
elates to the fact that most randomized trials to date have
ncorporated routine angiographic follow-up in either a
ajority (3,15,16) or at least a substantial proportion of the
tudy participants (5). Because SES have consistently been
ound to result in superior angiographic outcomes to PES,
t seems that the performance of angiographic follow-up
esults in a greater tendency toward revascularization of
orderline stenoses among PES-treated patients. The re-
ults of the SORT OUT II (Danish Organization on
andomized Trials with Clinical Outcome), which demon-
trated comparable rates of TLR among more than 2,000
Table 5. Association Between Site-Level Stent Preference, DES Type, and
<50% 5
SES PES SES
Cardiac death or MI (%) 11.6% 10.2% 7.7%
Stent thrombosis (%) 1.5% 1.2% 0.8%
TLR (%) 5.1% 3.1% 3.1%
*p value for interaction between the stent type and SES proportion derived from the final Cox survi
Abbreviations as in Table 4.atients randomized to SES or PES and did not undergo soutine angiographic follow-up (4), provides the most com-
elling evidence to date of this differential bias.
Our study both confirms the results of these previous
tudies and extends them in several important ways. First,
ur study is 1 of the largest studies to date to compare
lternative DES designs and incorporates a larger number of
tudy sites and broader geographic representation than any
revious study. Moreover, the all-inclusive nature of the
VENT registry allowed us to perform comparisons of
linical outcomes between PES and SES over a broad range
f patient and lesion types. The complexity of the popula-
ion included in our study is demonstrated by the high
roportions of patients with multi-lesion procedures
18.5%), chronic total occlusions (4.7%), saphenous vein
raft (7.0%), bifurcation lesions (11.1%), and thrombotic
esions (7.5%). In addition, among registry studies, the
VENT registry is the only 1 that incorporates routine
ssessment of cardiac enzymes and adjudication of all suspected
Is. Thus, our study provides strong evidence that the safety
f PES and SES are comparable, both in terms of stent
hrombosis as well as periprocedural infarction. Finally, the use
f clinical data—as opposed to administrative datasets—allows
or more thorough risk-adjustment as well as assessment of
ore specific mechanistic end points such as stent thrombosis
nd TLR.
mpact of site-level factors. Our study is the first to suggest
hat site-specific characteristics might play a role in deter-
ining clinical outcomes of PCI—particularly for end
oints related to repeat revascularization. In contrast to
revious studies that generally demonstrated either similar
r lower rates of clinically significant restenosis with SES
ompared with PES, in the EVENT registry we found that
he 1-year incidence of TLR was actually slightly higher with
ES than PES (4.4% vs. 3.3%, p  0.02)—a difference that
ersisted even after adjustment for clinical, angiographic, and
rocedural differences. However, after controlling for site stent
reference, the HR was markedly attenuated and the difference
as no longer statistically significant.
In light of the well-documented superior angiographic
erformance of SES compared with PES, these findings
r Clinical Outcomes
SES Proportion
0% >80%
PES SES PES p Value for Interaction*
10.2% 9.8% 9.3% 0.67
1.2% 1.0% 0.7% 0.34
3.0% 5.4% 4.8% 0.98
el.1-Yea
0%–8
val moduggest that factors other than angiographic restenosis
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775ight play an important role in determining rates of clinical
urrogates for restenosis, including TLR. Although it is not
ossible to determine the specific factors responsible for this
henomenon in this study, 1 possible explanation is that
ites that are more aggressive about screening for restenosis
ight preferentially choose to implant SES or that such
ites might have different thresholds for performing repeat
evascularization. Further study of surveillance patterns after
CI might provide additional insight into this novel find-
ng. In the interim, these findings suggest that analyses of
egistry data to compare rates of revascularization should be
ertain to adjust for potential site effects.
tudy limitations. This study has several important limita-
ions. As in any observational study, it is likely that our
ndings are impacted to some degree by unmeasured
onfounding. However, we believe that selection of a DES,
n contrast to many clinical decisions, might be driven by
actors beyond the operator’s control (such as hospital
ontracting and availability of product) and thus less likely
o be influenced by patient characteristics. In addition,
lthough we did attempt to adjust for a broad range of
ngiographic factors, these were determined on the basis of
elf-reported data rather than an objective, angiographic
ore laboratory. Finally, despite including more than 6,000
atients, our study had only modest power to detect
ifferences in rare events such as stent thrombosis.
onclusions
n this multicenter registry of nonemergent PCI with 2 types
f DES, we found that adjusted 1-year rates of both ischemic
omplications (death, MI, stent thrombosis) as well as clini-
ally important restenosis (TLR) were comparable for SES and
ES across a broad range of patient and lesion characteristics.
he finding that TLR seemed to be related to site character-
stics suggests that the correlation between TLR and angio-
raphic restenosis might be weaker than previously suggested
nd warrants further study.
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